These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19763644)

  • 1. In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.
    Liu CY; Lu CL; Huang YT; Liao CH; Hsueh PR
    Eur J Clin Microbiol Infect Dis; 2009 Dec; 28(12):1437-42. PubMed ID: 19763644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.
    Liu JW; Ko WC; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Chen YH; Lu PL; Sun W; Wang LS; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1414-7. PubMed ID: 22155819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
    Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
    Yang JC; Lee PI; Hsueh PR
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1369-75. PubMed ID: 20658256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
    Fernández-Canigia L; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2012 Oct; 11():29. PubMed ID: 23088592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
    Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y
    BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
    Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
    Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of tigecycline and nine other antibiotics against gram-negative bacterial isolates, including ESBL-producing strains.
    Jamal WY; Al Hashem G; Khodakhast F; Rotimi VO
    J Chemother; 2009 Jun; 21(3):261-6. PubMed ID: 19567345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
    Jones CH; Tuckman M; Keeney D; Ruzin A; Bradford PA
    Antimicrob Agents Chemother; 2009 Feb; 53(2):465-75. PubMed ID: 19015360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
    Biedenbach DJ; Beach ML; Jones RN
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E; Dalhoff A; Korfmann G
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
    Tubau F; Liñares J; Rodríguez MD; Cercenado E; Aldea MJ; González-Romo F; Torroba L; Berdonces P; Plazas J; Aguilar L; Delgado A; García-Escribano N;
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.